Ge Long Hui·2025-10-22 03:01Core Viewpoint - Huatai Securities published a research report indicating that Rongchang Biologics' core products have recently reported multiple clinical results, showcasing the global competitiveness of the company's pipeline and potential acceleration in overseas expansion [1] Group 1: Clinical Results - The oncology product line presented 11 research results at the 2025 ESMO, with 2 studies selected for Late-Breaking Abstract (LBA) [1] - Data readouts for Taitasip are expected to peak, with upcoming presentations at ACR/ASN [1] Group 2: Financial Projections - The company maintains its net profit forecasts for 2025 to 2027 at -346 million, 3 million, and 536 million respectively [1] - The target price for A-shares is maintained at 138.89 yuan, while the target price for H-shares has been raised from 137.1 HKD to 139.96 HKD, with a "Buy" rating upheld [1]